Y-mAbs Therapeutics Inc. (NASDAQ: YMAB) is -73.53% lower on its value in year-to-date trading and has touched a low of $2.94 and a high of $20.48 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The YMAB stock was last observed hovering at around $4.19 in the last trading session, with the day’s gains setting it 0.1% off its average median price target of $15.00 for the next 12 months. It is also 84.11% off the consensus price target high of $27.00 offered by 10 analysts, but current levels are -7.25% lower than the price target low of $4.00 for the same period.
Currently trading at $4.29, the stock is -9.93% and -59.20% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.48 million and changing 2.39% at the moment leaves the stock -65.27% off its SMA200. YMAB registered -75.12% loss for a year compared to 6-month gain of -59.94%.
The stock witnessed a -71.72% loss in the last 1 month and extending the period to 3 months gives it a -74.69%, and is 9.44% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.43% over the week and 16.88% over the month.
Y-mAbs Therapeutics Inc. (YMAB) has around 148 employees, a market worth around $181.38M and $43.40M in sales. Distance from 52-week low is 45.92% and -79.05% from its 52-week high. The company has generated returns on investments over the last 12 months (-64.10%).
Y-mAbs Therapeutics Inc. (YMAB) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Y-mAbs Therapeutics Inc. (YMAB) is a “Overweight”. 10 analysts offering their recommendations for the stock have an average rating of 2.20, where 3 rate it as a Hold and 0 think it is a “Overweight”. 6 of the analysts rate the stock as a “Buy”. 1 analysts have rated the stock as a Sell or Underperform.
Y-mAbs Therapeutics Inc. is expected to release its quarterly report on 02/23/2023.The EPS is expected to grow by 57.00% this year
Y-mAbs Therapeutics Inc. (YMAB) Top Institutional Holders
The shares outstanding are 43.72M, and float is at 38.06M with Short Float at 8.08%.
Y-mAbs Therapeutics Inc. (YMAB) Insider Activity
A total of 0 insider transactions have happened at Y-mAbs Therapeutics Inc. (YMAB) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider purchase by Rajah Vignesh, the company’s SVP & CMO. SEC filings show that Rajah Vignesh bought 1,195 shares of the company’s common stock on Nov 15 at a price of $4.92 per share for a total of $5884.0. Following the purchase, the insider now owns 4266.0 shares.
Y-mAbs Therapeutics Inc. disclosed in a document filed with the SEC on Feb 22 that Kruse Bo (EVP, CFO, Secretary & Treas.) sold a total of 4,000 shares of the company’s common stock. The trade occurred on Feb 22 and was made at $7.85 per share for $31400.0. Following the transaction, the insider now directly holds 0.18 million shares of the YMAB stock.
Still, SEC filings show that on Feb 09, Gad Thomas disposed off 64,276 shares at an average price of $6.96 for $0.45 million. The insider now directly holds 565,032 shares of Y-mAbs Therapeutics Inc. (YMAB).
Y-mAbs Therapeutics Inc. (YMAB): Who are the competitors?
The company’s main competitors (and peers) include Novan Inc. (NOVN) that is trading -83.48% down over the past 12 months and Bristol-Myers Squibb Company (BMY) that is 37.75% higher over the same period. Gilead Sciences Inc. (GILD) is 20.94% up on the 1-year trading charts.